A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2862 participants.
Also called NCT06642623
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,862 participants
- Sponsor
- Registry
-
NCT06642623
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06642623. Randomized; no masking; primary purpose treatment. Start 2024-01-22 (actual); primary completion 2029-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
- Acronym
- ENVELOP
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Cardiovascular Diseases
- Condition
- Kidney Diseases
- Intervention (Drug)
- Enavogliflozin
- Intervention (Drug)
- Dapagliflozin or Empagliflozin
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct06642623- Content hash
59554baba6a61c7301a46200b795e5c79bf9b892537b7fa84e98833b93143c45